Insufficient Evidence to Conclude Whether Anti–Tumor Necrosis Factor Therapy Increases the Risk of Lymphoma in Crohn's Disease
published online 25 May 2009.
Refers to article:
Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
, 27 January 2009
Corey A. Siegel, Sadie M. Marden, Sarah M. Persing, Robin J. Larson, Bruce E. Sands
Clinical Gastroenterology and Hepatology
August 2009 (Vol. 7, Issue 8, Pages 874-881) Abstract |
Full Text |
Full-Text PDF (406 KB)
|
Add-Ons
Siegel et al1 reported an increased risk of lymphoma in Crohn's disease patients receiving combination therapy with anti–tumor necrosis factor (TNF) agents and immunomodulators. We believe that no definite conclusions can be drawn from this meta-analysis for the following reasons.
⁎Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
PREVIEW
Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis